Tenderwize
Wróć do wyszukiwania

Discount Agreement for Choriongonadotropin alfa

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 278 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-10 - Choriongonadotropin alfa

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or framework maximum is provided. Bidders cannot assess potential revenue or pricing strategy.

Since all qualified applicants can participate, many competitors may join, potentially limiting market share for each c...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products containing Choriongonadotropin alfa to patients insured by TK, HEK, and hkk.
  • Conclusion of a discount agreement under § 130a Abs. 8 SGB V with uniform terms for all participating pharmaceutical entrepreneurs.
Pokaż pełne podsumowanie

This is an Open House procedure by Techniker Krankenkasse (TK) and associated health insurers for discount agreements on the active substance Choriongonadotropin alfa. The contract is open to all qualified pharmaceutical entrepreneurs under uniform terms, with no exclusivity. The maximum contract duration is 24 months from June 1, 2025 to May 31, 2027. Submissions can be made at any time during the period, but must be submitted via email with qualified electronic signature or by post. The estimated contract value is not provided. The notice clarifies this is not a public procurement procedure under EU directives; legal challenges fall under social courts.

Ryzyka

No estimated value or framework maximum is provided. Bidders cannot assess potential revenue or pricing strategy.

Since all qualified applicants can participate, many competitors may join, potentially limiting market share for each c...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG for the offered medicinal product.
  • Must have a registered office in Germany, another EU member state, or a EEA state (§ 9 Abs. 2 Satz 1 AMG).
  • Must hold a valid marketing authorisation for the relevant medicinal product or be otherwise entitled to place it on the market.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria; contracts are offered to all qualified pharma entrepreneurs.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Discount Agreement for Choriongonadotropin alfa

Open House procedure for concluding discount agreements with all suitable pharmaceutical entrepreneurs for the active substance Choriongonadotropin alfa. Uniform terms apply; no exclusivity is granted.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria; contracts are offered to all qualified pharma entrepreneurs.

Termin

Deadline May 30, 2027

Szczegóły zamówienia

Data publikacji
22 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
262953-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3